Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

U.S. House committee ‘may reconsider’ WHO cancer agency funds

U.S. congressional committee members warned that Washington’s funding of the World Health Organization’s cancer research agency could be halted unless it is more open about its operations.

Read More »

Lilly’s Cyramza meets main goal for gastric cancer

Eli Lilly & Co.’s Cyramza met the main study goal but failed to improve survival rates in a late-stage trial for gastric cancer.

Read More »

Fully Loaded With Nearly 500 Employees in Rockville, GlaxoSmithKline Chief Lays Out 2018 Goals

With one year of operations now under its belt since the grand opening, pharma giant GlaxoSmithKline has a bold future planned for its research and development facility in Maryland.

Read More »

Ex-Genentech Employees’ Denali Breaks 2017 IPO Records, Raises $250 Million

Denali Therapeutics – launched in May 2015 by three former Genentech researchers – went public, raising $250 million with shares priced at $18.

Read More »

Breast cancer drug superior to chemo in study

Pfizer’s talazoparib for advanced breast cancer was demonstrated to be superior to chemotherapy in a late-stage study.

Read More »

Philippines to seek refund of $59 million from Sanofi amid vaccine risk

The Philippines will seek the return of 3 billion pesos ($59 million) it paid French drugmaker Sanofi for a dengue vaccine used to immunize hundreds of thousands of children that Sanofi has said could worsen the disease in some cases.

Read More »

Roche study: Cancer ‘Velcro’ halts T-cell attack

Roche scientists may have discovered why some tumors resist new immunotherapy drugs as well as a possible means of turning the tables to incite a T-cell attack.

Read More »

Gilead, Kite to acquire Cell Design Labs

Gilead Sciences and its cell therapy subsidiary Kite Pharma agreed to acquire Cell Design Labs.

Read More »

Halozyme, Alexion Reach R&D Deal

San Diego’s Halozyme Therapeutics tied up a licensing agreement with Connecticut-based Alexion Pharmaceuticals that could net the company $680 million.

Read More »

Spark, Pfizer’s Gene Therapy Hemophilia B Drug Stuns in Trial

Philadelphia-based Spark Therapeutics, with its partner Pfizer, published interim data from its Phase I/II clinical trial of a gene therapy for hemophilia B in The New England Journal of Medicine.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!


Ad Right Bottom